2010-27: THE HYDRUS II TRIAL: A PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE HYDRUS IMPLANT FOR LOWERING INTRAOCULAR PRESSURE IN GLAUCOMA PATIENTS UNDERGOING CATARACT SURGERY
Glaucoma is a leading cause of irreversible blindness, and is associated with increased intraocular pressure (IOP). Ivantis has developed the HydrusTM Aqueous Implant as a surgical alternative to hypotensive glaucoma medications. The Hydrus Implant is designed to enhance the function of the natural aqueous outflow pathway of the eye in order to reduce IOP. The objective of this clinical trial is to demonstrate the ability of the CE-marked HydrusTM Aqueous Implant to lower intraocular pressure in glaucoma patients undergoing cataract surgery.